AbCellera Biologics Inc. ABCL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s EPS (diluted)?
- AbCellera Biologics Inc. (ABCL) reported EPS (diluted) of -$0.14 in Q1 2026.
- How has AbCellera Biologics Inc.'s EPS (diluted) changed year-over-year?
- AbCellera Biologics Inc.'s EPS (diluted) increased by 6.7% year-over-year, from -$0.15 to -$0.14.
- What is the long-term trend for AbCellera Biologics Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s EPS (diluted) has grown at a 1.4% compound annual growth rate (CAGR), from $0.47 to -$0.49.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.